[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438243":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":23,"studyPopulation":24,"armGroups":19,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":49,"collaborators":19,"id":51,"slug":19,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":19,"studyType":63,"phases":19,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"National Cancer Centre, Singapore","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":19},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Percentage of patients with successful model generation for each tumour subtype.","Patients enrolled on study will undergo resection or biopsy of fresh tumour tissue to obtain cells for the generation of models.","8 years.",{"measure":14,"description":15,"timeFrame":12},"Rates of radiological response from QPOP-directed treatment regimens.","Complete and partial clinical response and stable disease.",{"measure":17,"description":18,"timeFrame":12},"Survival outcomes from QPOP-directed treatment regimens.","Overall survival, progression-free survival.",null,{"allocation":19,"interventionModel":19,"interventionModelDescription":19,"primaryPurpose":19,"observationalModel":21,"timePerspective":22,"maskingInfo":19},"CASE_ONLY","PROSPECTIVE","Hypothesis: Ex vivo drug testing on patient-derived models using QPOP can identify drug sensitivities and combinations which may have clinical efficacy against sarcomas and melanomas.\n\nSpecific aim 1: To derive patient models, both two- and three-dimensional, of sarcomas and melanomas\n\nSpecific aim 2: To perform ex vivo drug testing on patient models of sarcoma and melanoma using QPOP\n\nSpecific aim 3: To assess the efficacy of phenotype directed therapy using QPOP to assign treatment after progression on standard-of-care treatment in sarcoma and melanoma","Patient aged between 21 to 99 diagnosed with sarcoma or melanoma.",[26],{"name":27,"affiliation":5,"role":28},"Valerie Shiwen Yang, BSc, MB BChir, PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":19,"email":33},"CONTACT","+65 6436 8088","valerie.yang.s.w@singhealth.com.sg",[35],{"facility":36,"status":37,"city":38,"state":19,"zip":39,"country":38,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"National Cancer Centre Singapore","RECRUITING","Singapore","169610","SG",{"type":42,"coordinates":43},"Point",[44,45],103.85007,1.28967,{"lat":45,"lon":44},[48],{"name":27,"role":31,"phone":19,"phoneExt":19,"email":19},{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100438243",false,"NCT04986748","Using QPOP to Predict Treatment for Sarcomas and Melanomas","Q-SAM (Using QPOP to Predict Treatment for Sarcomas and Melanomas)","Inclusion Criteria:\n\n* Diagnosis of sarcoma or melanoma\n* At least 1 tumour lesion amenable to fresh biopsy or resection\n* Signed informed consent from patient or legal representative\n* Able to comply with study-related procedures\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria if patients meet the inclusion criteria","ALL","21 Years","99 Years",{"count":61,"type":62},100,"ESTIMATED","OBSERVATIONAL","This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.\n\nEnrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.",[66,67],"Sarcoma","Melanoma",[69,70,71,72,73],"Tumour-derived models","Organoids","Ex vivo drug testing","Personalised therapy","QPOP","2025-06-29",{"date":76,"type":77},"2025-07-01","ACTUAL",{"date":79,"type":77},"2020-09-08",{"date":81,"type":62},"2028-12-31",{"name":5,"class":6},1]